BioCentury
ARTICLE | Clinical News

CAmB: Phase IIa started

February 22, 2016 8:00 AM UTC

Matinas said the NIH began an open-label, U.S. Phase IIa trial to evaluate oral MAT2203 for 14 days in up to 16 patients who are refractory or intolerant to standard non-IV therapies. ...